NanoGhost Overview
NanoGhost is a drug-delivery technology that uses adult stem cells to transport medicine directly to the tumor site. The technology has already proven successful in treating pancreatic, lung, breast, prostate, and brain cancer in mice. The platform is based on nano-vesicles, termed Nano-Ghosts (NGs), which are technologically reconstructed from the cell membranes of naturally targeted allogeneic mesenchymal stem cells (MSCs), after removing their cytoplasm and nuclei. The NGs' safety and targeting capabilities rely on their retention of the surface-associated mechanisms that govern MSCs' well-documented allogeneic tolerability and targeting of multiple inflamed and malignant tissues. The NanoGhost technology was developed by Professor Marcel Machluf, the faculty dean of Biotechnology & Food Engineering at the Technion-Israel Institute of Technology. Professor Machluf developed the technology in her lab at the Technion and set up a start-up as a spin-off from the university to commercialize the technology. Israel's Ministry of Science and Technology named NanoGhost as one of Israel's 60 most impactful developments. The NanoGhost technology has been patented in the United States and Europe, with additional patents pending in India and China.
Cumulative Funding Raised Over Time ($)
$5.0MDec 2019
$9.0MJun 2023
Latest News
How to reduce cancer drug dosage a millionfold - ISRAEL21c
growth-positive
NanoGhost: Delivering the greatest things in the smallest packages
NanoGhost, a company founded by Prof. Marcelle Machluf and Yonatan Malca, is developing a drug-delivery technology based on adult stem cells. The technology, called NanoGhost, uses modified adult stem cells loaded with medicine to target cancer cells. The stem cells are emptied and shrunk to nano-size, creating nano-ghost vesicles that act as trojan horses to deliver medicine directly to the cancer cells. NanoGhost has raised $5 million in its seed round, with aMoon serving as a lead investor. The company aims to reach animal testing within a year and conduct clinical trials by 2023. The founders emphasize that there is still work to be done, but they believe the system works and will be effective in humans.
InvestmentExpand
growth-positive
Prof. Marcelle Machluf Is Adapting Nano-Ghost Research to Trap COVID-19 - American Technion Society
Technion Professor Marcelle Machluf has adapted her nano-ghost research to trap COVID-19. The companys growth is expected to be positive as a result of this research adaptation. The key theme of the article is research. The key issues discussed in the article are expansion and recruitment. The event described in the article does not have a specific date mentioned. The confidence level of the answer is 8.
Expand
growth-positive
Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company
Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts. NanoGhosts turns stem cells into a drug delivery system that specifically targets cancerous tumors. The technology is based on the founders research at the Technion Israel Institute of Technology. NanoGhosts research has shown promising results in prolonging the survival of animals with cancer. AMoon is a venture capital firm founded in 2016 and its portfolio includes other healthcare and technology companies.
Investment
growth-positive
'Ghost' cell startup that targets deadliest cancers gets funding boost
aMoon, a health-tech fund, has made a $5 million investment in a new venture set up by Prof. Marcelle Machluf to develop her NanoGhost technology, which aims to shrink the deadliest forms of cancer by precisely targeting the tumors. The NanoGhost technology, developed by Machluf at the Technion-Israel Institute of Technology, uses mesenchymal stem cells to create nano-vehicles filled with anti-cancer drugs that are injected into the bloodstream and released directly into the tumors. Lab experiments have shown promising results in reducing tumor size. aMoons investment will support the commercialization of the technology.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $9M |
| Last funding | $4M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.nano-ghost.com/ |
| Careers | Careers page |
Locations
Beni Ga'on St 12, Netanya, Israel
Photos & Videos
3 item(s)
NanoGhost Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
Materials & SubstancesBiologicalsCellsTags (11)
targeted-cancer-therapycancertargeted-therapystem-cellsdrug-deliverynanotechnologyimmunotherapytreatmentspharmaceuticalsbiotechnologygeneticsGeographic Markets
EuropeIndiaChinaUnited StatesNanoGhost Financials
$9M
Total funding
Undisclosed
Capital raised
$4M
Last funding
Seed
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$5.0MDec 2019
$9.0MJun 2023
Private Equity Funding
Seed
Jun 2023
$4M
New Gate Capital
Seed
Dec 2019
$5M
aMoon Fund
NanoGhost Lifecycle
Cumulative Funding Raised Over Time
$5.0MDec 2019
$9.0MJun 2023
All Events
Seed
Jun 2023
$4M
New Gate Capital
Seed
Dec 2019
$5M
aMoon Fund
NanoGhost News
7 articlesHow to reduce cancer drug dosage a millionfold - ISRAEL21c
growth-positive
NanoGhost: Delivering the greatest things in the smallest packages
NanoGhost, a company founded by Prof. Marcelle Machluf and Yonatan Malca, is developing a drug-delivery technology based on adult stem cells. The technology, called NanoGhost, uses modified adult stem cells loaded with medicine to target cancer cells. The stem cells are emptied and shrunk to nano-size, creating nano-ghost vesicles that act as trojan horses to deliver medicine directly to the cancer cells. NanoGhost has raised $5 million in its seed round, with aMoon serving as a lead investor. The company aims to reach animal testing within a year and conduct clinical trials by 2023. The founders emphasize that there is still work to be done, but they believe the system works and will be effective in humans.
InvestmentExpand
growth-positive
Prof. Marcelle Machluf Is Adapting Nano-Ghost Research to Trap COVID-19 - American Technion Society
Technion Professor Marcelle Machluf has adapted her nano-ghost research to trap COVID-19. The companys growth is expected to be positive as a result of this research adaptation. The key theme of the article is research. The key issues discussed in the article are expansion and recruitment. The event described in the article does not have a specific date mentioned. The confidence level of the answer is 8.
Expand
growth-positive
Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company
Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts. NanoGhosts turns stem cells into a drug delivery system that specifically targets cancerous tumors. The technology is based on the founders research at the Technion Israel Institute of Technology. NanoGhosts research has shown promising results in prolonging the survival of animals with cancer. AMoon is a venture capital firm founded in 2016 and its portfolio includes other healthcare and technology companies.
Investment
growth-positive
'Ghost' cell startup that targets deadliest cancers gets funding boost
aMoon, a health-tech fund, has made a $5 million investment in a new venture set up by Prof. Marcelle Machluf to develop her NanoGhost technology, which aims to shrink the deadliest forms of cancer by precisely targeting the tumors. The NanoGhost technology, developed by Machluf at the Technion-Israel Institute of Technology, uses mesenchymal stem cells to create nano-vehicles filled with anti-cancer drugs that are injected into the bloodstream and released directly into the tumors. Lab experiments have shown promising results in reducing tumor size. aMoons investment will support the commercialization of the technology.
Investment
growth-positive
Israeli Scientist Discusses Cancer Treatment - Jewish Exponent
Marcelle Machluf, the dean of biotechnology and food engineering at the Technion-Israel Institute of Technology, is working on an innovative cancer treatment called nanoghosts. Nanoghosts, a drug-delivery technology that uses adult stem cells to transport medicine directly to the tumor site, have already proven successful in treating various types of cancer in mice. The technology has won Machluf numerous honors and awards. The next step is to raise funds for the company and proceed to clinical trials. Machluf believes that nanoghosts have the potential to be a game changer in the field of cancer treatment, improving drug efficacy and reducing side effects. She also discusses her experiences as a woman and minority in the field of science and offers advice to others interested in pursuing STEM.
InvestmentExpand
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/The-woman-behind-nanoghosts-552974
Prof. Marcelle Machluf, a scientist at the Technion-Israel Institute of Technology, had her medical articles initially rejected by journals but has since been recognized for her research on tissue engineering and cancer drug delivery. Her lab studies have shown that her modified stem cells called nanoghosts can kill every type of solid tumor. The rejection by journals was seen as a growth-negative impact on the company, but the subsequent recognition and publication of her work have had a growth-positive impact. The key theme of the article is the achievements and contributions of Prof. Marcelle Machluf in the field of medical research. The key issues discussed in the article are related to customers, as the article mentions the testing of her lab studies on patients in the next year or two. The date of the event described in the article is not specified. The confidence in the answer is 8.
Customers
NanoGhost Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 12 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
NanoGhost Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Hilla Gorokhovsky |
| Registrar ID | 516071149 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-12-04T00:00:00.000Z |
| Created | 2019-12-25T00:00:00.000Z |
| Claimed | Yes |